Bifidobacterium animalis subsp. lactis HN019 and Improved Stool Consistency

Doses used in studies

CFU/day: 1 million–10 billion (median 5.0 billion, IQR 2.5 billion–7.5 billion) — 2 studies

Time to effect

Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 1 of 2 studies

Safety in these studies

Overall tolerabilityReported
Three unlikely related AEs-2 with low-dose HN019 and 1 with placebo-were followed until full recovery.
from: Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic
Overall tolerabilityReported
The probiotic-containing formulae were well-tolerated: there were no cases of diarrhoea or differences in stool frequency or characteristics, no differences in infant growth or temperament, and no treatment-related adverse events.
from: Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis
diarrhoeaReported
there were no cases of diarrhoea
from: Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis
hospitalisationReportedSerious adverse event
No infants required hospitalisation.
from: Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis

2 of 2 papersPopulation:

Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis HN019 reduced upper respiratory tract infections in Chinese infants.